Joseph M Scandura, MD, PhD

Associate Professor of Medicine

Hematology and Medical Oncology (Medicine)

Contact & profiles

Appointments

Associate Professor of MedicinePrimary
Medicine · 2015–
Physician
NewYork-Presbyterian Hospital

Past Appointments

Assistant Professor of Clinical Medicine
Medicine · 2011–2015
Assistant Professor of Medicine
Medicine · 2006–2011
Instructor in Clinical Medicine
Medicine · 2004–2006

Show all 5

Fellow in Medicine
Medicine · 1999–2003
Clinical Associate in Medicine
Medicine · 1998–1999

Centers

Clinical & Translational Science Center
Sandra and Edward Meyer Cancer Centerresearch
Cancer Therapeutics

Education

M.D., Ph.D., Biochemistry
Temple University School of Medicine, 1997
M.S., Biomedical Engineering
University of Pennsylvania, 1992
B.S., Electrical Engineering
Cornell University, 1987

Highlights

1
Leukemia · 2021
GAGhaith Abu-Zeinah JMJoseph M Scandura
PMID: 34625712DOISenior author42 citations
2
Leukemia · 2024
DCDaniel Chimin Choi GAGhaith Abu-Zeinah FCFranco Castillo Tokumori JMJoseph M Scandura
PMID: 39244632PMCID: PMC11984324DOISenior author12 citations
3
Blood · 2020
NPNicole Politowska MolleGAGhaith Abu-Zeinah NMNassima Messali RSRyan Schreiner+1 more →JMJoseph M Scandura
PMID: 32548608PMCID: PMC7453150DOISenior author17 citations

Publications

Funding

31 View NIH portfolio on RePORTER ↗

Active

6 grants

PI
Controlling the Niche to Control Clonal Hematopoiesis
National Heart, Lung, and Blood Institute · 2025–2029
R01HL175556-02
MPI
Myeloproliferative Neoplasms-Research Consortium
National Cancer Institute · 2025–2028 · via Icahn School of Medicine at Mount Sinai
P01CA108671-18
PI
Quantification of Circulating CD34⁺ Hematopoietic Stem and Progenitor Cells from Viably Frozen PBMCs Obtained during XPORT-MF-044
Karyopharm Therapeutics, Inc. · 2026–2028Contract
SRA 260569-01
PI
Sumitomo Dainippon Pharma Oncology, Inc - SRA
Sumitomo Dainippon Pharma Oncology, Inc · 2024–2026Contract
SRA 225786-01
MPI
Measuring Myeloproliferative Neoplasms Stem and Progenitor Cell Clonal Fitness to predict disease outcome
American Society of Hematology Inc · 2024–2026
ASH 240245-02
PI
Creating a framework for interpreting changes in megakaryocyte features in patients with myelofibrosis treated with a novel BET inhibitor
Constellation Pharmaceuticals · 2024–2025Contract
SRA 234139-01

Completed grants (25)

PI
Targeting MPN and Progenitor Cells
AbbVie Inc. · 2022–2025Contract
SA 223160-01
KP
Defining malignant hematopoiesis via single-cell multi-omics
Office of the Director, NIH · 2020–2025
DP5OD029619-02
Co-I
Endothelial cell transplantation for multi-organ repair to counter radiation injury
National Institute of Allergy and Infectious Diseases · 2018–2025
U01AI138329-01
PI
Immunologic Eradication of Myeloproliferative Neoplasm Stem Cells
Daedalus Fund for Innovation (Weill Cornell) · 2022–2024BioPharma Alliance
BP 226449-02
PI
Tracking MPN Fitness to speed development of disease modifying agents for MPNs
MPN Research Foundation · 2023–2024
MPN 230492-01
PI
Early intervention for the prevention of blood cancer development.
Starr Cancer Consortium · 2022–2023
I15-0026
Co-I
Weill Cornell Training Program in Stem Cell Biology and Regenerative Medicine
New York State Stem Cell Science (NYSTEM) · 2018–2023
DOH01-C32558GG-3450000
Co-I
Clinical and Translational Science Center - UL1
National Center for Advancing Translational Sciences · 2017–2022
UL1TR002384-01
PI
MPN Stem and Progenitor Cell Clonal Fitness as Predictors of Progression
MPN Research Foundation · 2021–2022
MPN 211963-01
Co-I
Vascular Niche Platform to Expand Hematopoietic Stem and Progenitor Cells Engineered to Cure Sickle Cell Disease
New York State Stem Cell Science (NYSTEM) · 2015–2020
C0 30160
KP
SPORE in Bladder Cancer
National Cancer Institute · 2018–2020 · via Sloan-Kettering Institute for Cancer Research
P50CA221745-02
Co-I
Deciphering Molecular Determinants of Vascular Heterogeneity for Organ Repair
National Heart, Lung, and Blood Institute · 2014–2020
R01HL128158-05
Co-I
Molecular Determinants of endothelial transition into engraftable hematopoietic cells
National Heart, Lung, and Blood Institute · 2018–2020
R01HL139056-01A1
PI
Curing MDS using Hematopoietic Cells Reprogrammed from Autologous, Normal Endothelial Cells
Henry and Marilyn Taub Foundation · 2016–2020
HMTF 16060851-03
Co-I
Conversion of Human Adult Endothelium Into Hematopoietic Stem Cells for Immune Cell Engineering
Tri-Institutional Stem Cell Initiative (Weill Cornell) · 2016–2019
2016-013
Co-I
Rejuvenation of Aged Vascular Niches to Enhance Hematopoietic Function and Treat Hematopoietic Malignancies
Leukemia & Lymphoma Society · 2017–2018
R0859-18
PI
Rapid Prototyping of MPN Phenotypes Using Endothelium-Derived, Reprogrammed Hematopoietic Cells
Tri-Institutional Stem Cell Initiative (Weill Cornell) · 2016–2018
TSCI 2016-024
PI
Personalizing Epigenetic Therapy for AML
Leukemia & Lymphoma Society · 2013–2018
LLS 170480-05
Co-I
A Shared Facility for the Derivation, Validation, and Distribution of Stem Cells for Disease Modeling
New York State Stem Cell Science (NYSTEM) · 2014–2018
C029156
KP
Identification of Vascular-Derived Signals for Alveolar Lung Repair
National Heart, Lung, and Blood Institute · 2013–2017
R01HL119872-03
PI
Promoting Hematopoietic Regeneration After Chemo by Rescheduling Homeostasis
National Heart, Lung, and Blood Institute · 2014–2016
R56HL116436-01A1E
KP
Center on the Microenvironment and Metastasis
National Cancer Institute · 2009–2015 · via Cornell University - Ithaca
U54CA143876-04
PI
Genome-Wide Identification of DNA Methylation Biomarkers in AML
National Cancer Institute · 2012–2014
R21CA159175-02
Sub-PI
A Mouse Model for Human Gastrointestinal Stromal Tumor
National Cancer Institute · 2010–2014 · via Sloan-Kettering Institute for Cancer Research
R01CA102774-09
PI
p57KIP2 in Hematopoiesis and Leukemogenesis
NCI · 2005–2010 · via NIH RePORTER
K08CA104082-06

Clinical research

Active

2 studies

PI
A Phase 1/2, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral Nuvisertib (TP-3654) in Patients With Intermediate or High-Risk Primary or Secondary Myelofibrosis
PHASE1; PHASE2 · Sumitomo Dainippon Pharma Oncology, Inc · OPEN TO ACCRUAL (as of 2023)
Myelofibrosis
NCT04176198
PI
Blood, Bone Marrow, and Tissue Sample Collection for Studies in Myeloproliferative Disorders.
Weill Medical College of Cornell University · OPEN TO ACCRUAL (as of 2020)

Completed & closed trials (7)

PI
A Phase 1, Open-Label, Multicenter Study of INCB160058 in Participants With Myeloproliferative Neoplasms
PHASE1 · Incyte Corporation · CLOSED TO ACCRUAL (as of 2026)
Myeloproliferative Neoplasms
NCT06313593
PI
A 2-tiered, Phase 2, Rule-based, Intra-patient Dose Escalation Study to Investigate Safety and Feasibility of Vactosertib (TEW-7197) in the Treatment of Anemic Patients With Philadelphia Chromosome-negative MPNs (Ph-neg MPNs)
PHASE2 · Weill Medical College of Cornell University · IRB STUDY CLOSURE (as of 2026)
Myeloproliferative Neoplasm
NCT04103645
PI
A Phase 1/2 Study of CPI-0610, a Small Molecule Inhibitor of BET Proteins: Phase 1 (Dose Escalation of CPI-0610 in Patients With Hematological Malignancies) and Phase 2 (Dose Expansion of CPI-0610 With and Without Ruxolitinib in Patients With Myeloproliferative Neoplasms)
PHASE1; PHASE2 · Constellation Pharmaceuticals · IRB STUDY CLOSURE (as of 2025)
Myelofibrosis; Leukemia, Myelocytic, Acute; Myelodysplastic/Myeloproliferative Neoplasm; Myelodysplastic Syndrome (MDS); Preleukemia; Primary Myelofibrosis; Myeloproliferative Disorders; Bone Marrow Disease; Hematological Disease; Precancerous Conditions; Neoplasms; Leukemia; Neoplasms by Histologic Type; Essential Thrombocytosis
NCT02158858
PI
An Open-Label, Multicenter, Extension Study for Patients Previously Enrolled in Studies With Pelabresib
PHASE3 · Constellation Pharmaceuticals · CLOSED TO ACCRUAL (as of 2024)
Hematologic Malignancy; Solid Tumor; Advanced Malignancies
NCT06401356
PI
Data-driven model for differentiating myeloproliferative neoplasms
Weill Medical College of Cornell University · CLOSED TO ACCRUAL (as of 2024)
PI
A Phase 3 Study of the Hepcidin Mimetic Rusfertide (PTG-300; TAK-121) in Patients With Polycythemia Vera
PHASE3 · Protagonist Therapeutics, Inc. · CLOSED TO ACCRUAL (as of 2024)
Polycythemia Vera
NCT05210790
PI
A Phase 3, Randomized, Double-blind, Active-Control Study of Pelabresib (CPI-0610) and Ruxolitinib vs. Placebo and Ruxolitinib in JAKi Treatment Naive MF Patients
PHASE3 · Novartis Pharma AG · CLOSED TO ACCRUAL (as of 2023)
Myelofibrosis; Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis
NCT04603495

Available technologies

2 View full WCM portfolio ↗

Media highlights

Beyond Symptom Relief: How MPN Treatment Goals Are Changing
Patient Power · September 22, 2026

External relationships

Advisory/Scientific Board Member

Cancer Research & Treatment Fund Inc · Incyte Corporation · Karyopharm Therapeutics, Inc. · Novartis Pharmaceuticals Corporation · Sumitomo Dainippon Pharma Oncology, Inc · Takeda Pharmaceutical Company Limited

Other

Calico Life Sciences LLC · Sumitomo Dainippon Pharma Oncology, Inc · Takeda Pharmaceutical Company Limited